In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • The tumor board report summarized a lot of information into a very easy to read and understandable format. It provided contact information for additional treatment options which we will be pursuing. Lola Rahib was very efficient in obtaining all my medical records and responded quickly to our initial inquiry.

    Tony
    Pancreatic cancer patient

  • Cancer Commons helped give me peace of mind with my treatment decision. Chief scientist Emma Shtivelman’s expert, science-based opinion made such logical sense, and it also felt right in my soul.

    Ellen
    Breast cancer patient

  • The team at Cancer Commons provided options above and beyond what the local care team had offered. Such a great service for patients.

    Anonymous

  • Emma has been so helpful and kind to my wife.

    Husband of cancer patient

  • Cancer Commons is extremely engaged and proactive. Its professionals have directed us towards interesting avenues to explore in our search for additional treatment options.

    Mark Bezner
    Husband of stage IV ovarian cancer patient

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.